Evidence map›Paper›PMID 39351366›Full record

ArticlePeerJ2024

Association of

Ziyang Liu, Yang Zhou, Menglong Jin, Shuai Liu, Sen Liu, Kai Yang, Huayin Li, Sifu Luo, Subinuer Jureti, Mengwei Wei and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ziyang Liu *The First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Yang Zhou *The First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Menglong JinState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi, Xinjiang, China.
Shuai LiuThe First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Sen LiuThe First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Kai YangThe First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Huayin LiThe First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Sifu LuoThe First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Subinuer JuretiThe First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Mengwei WeiThe First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Zhenyan FuThe First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dyslipidemia plays a very important role in the occurrence and development of cardiovascular disease (CVD). Genetic factors, including single nucleotide polymorphisms (SNPs), are one of the main risks of dyslipidemia. 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is not only the rate-limiting enzyme step of endogenous cholesterol production, but also the therapeutic target of statins. Methods: We investigated 405 Han Chinese and 373 Uyghur people who took statins for a period of time, recorded their blood lipid levels and baseline data before and after oral statin administration, and extracted DNA from each subject for SNP typing of Results: In this study, for rs17671591, the CC Conclusion: We found that

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesPolymorphism, Single NucleotideAdultAgedCentral Asian PeopleChinaCholesterol, LDLDyslipidemiasEast Asian PeopleFemaleHumansHyperlipidemiasLipidsMaleMiddle AgedCholesterol, LDLHMGCR protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesLipidsCardiovascular diseaseChinaHMGCRLipidMulti-ethnic populationSingle nucleotide polymorphismsSNPStatinStatin resistanceStatin response

Identifiers

PMID39351366
PMCPMC11441381

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.